R&D channel feed

FDA lifts clin­i­cal hold on Foghorn’s study for blood and bone mar­row can­cer treat­ment

Last year

As­traZeneca, Dai­ichi Sankyo’s En­her­tu im­press­es in 'game-chang­ing' study with many can­cers: #AS­CO23

Last year

Mod­er­na, Mer­ck say their can­cer vac­cine re­duces metas­tases by 65% in PhII study of high-risk melanoma: #AS­CO23

Last year

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

Last year
Cell/Gene Tx

J&J’s blad­der can­cer drug Balver­sa cuts the risk of death in fol­low-up tri­al: #AS­CO23

Last year

As­traZeneca moves ear­ly for full ap­proval with an­ti­co­ag­u­lant re­ver­sal drug An­dexxa af­ter pos­i­tive PhIV da­ta

Last year
FDA+

Bris­tol My­er­s' Op­di­vo keeps can­cer at bay in more lym­phoma pa­tients than Seagen's Ad­cetris in PhI­II: #AS­CO23

Last year

Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

Last year

As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

Last year

Full TIG­IT da­ta from Gilead, Ar­cus show low­er PFS rates than De­cem­ber read­out: #AS­CO23

Last year

Keytru­da be­fore and af­ter lung can­cer surgery cuts re­lapse risk by 42%, but doesn’t im­prove sur­vival: #AS­CO23

Last year

Grail’s blood test charts path for di­ag­nos­ing pa­tients sus­pect­ed of hav­ing can­cer in large study: #AS­CO23

Last year

No­var­tis’ Kisqali pre­vents breast can­cer from com­ing back for longer — but can it best Eli Lil­ly’s Verzenio? #AS­CO23

Last year

Green­Light Bio­sciences se­cures merg­er as it looks to go pri­vate

Last year
Manufacturing

FDA lifts hold on Mol­e­c­u­lar Tem­plates’ mul­ti­ple myelo­ma tri­al af­ter less than two months

Last year
FDA+

As­traZeneca gives up on late-stage IL-23 drug due to tri­al de­lays, com­pet­i­tive land­scape

Last year

FDA ap­proves As­traZeneca's Lyn­parza com­bo for adults with BR­CA-mu­tat­ed prostate can­cer

Last year

Pre­ci­sion Bio­Sciences to meet with FDA af­ter tout­ing al­lo­gene­ic CAR-T win

Last year
Cell/Gene Tx

Vi­o­let Ther­a­peu­tics snags $10.6M in seed fund­ing for plat­forms that go be­yond sin­gle-cell se­quenc­ing

Last year

Glyscend Ther­a­peu­tic­s' ear­ly da­ta show poly­mer mim­ics ben­e­fits of surgery in type 2 di­a­betes, obe­si­ty

Last year

Sanofi rolls out PhII mul­ti­ple scle­ro­sis da­ta that will take the phar­ma in­to piv­otal stud­ies next year

Last year
Pharma

Chi­na's mar­ket reg­u­la­tor fines, con­fis­cates rev­enue from phar­mas for mo­nop­o­liz­ing APIs for ep­i­neph­rine

Last year
China

Ake­bia to re­file ane­mia drug vadadu­s­tat af­ter FDA de­nied ap­peal

Last year

C4 Ther­a­peu­tics gets $35M from Bet­ta Phar­ma­ceu­ti­cals to de­vel­op and mar­ket NSCLC drug in Chi­na

Last year
Deals
China
First page Previous page 81828384858687 Next page Last page
A service from the Financial Times